Neuralink, Elon Musk's neurotechnology company, has achieved a significant milestone by receiving Breakthrough Device ...

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment ...

The device helps identify NSCLC subjects who are likely to benefit from Daiichi Sankyo and AstraZeneca’s Datroway’s treatment ...

The company said that its applications can be extended to individuals affected by ALS, stroke, spinal cord injury, cerebral ...

The biotech company Roche is receiving support towards its efforts to advance cancer diagnosis and digital pathology ...

The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA ...

Neuralink said on social media that it received FDA breakthrough device designation for treating individuals with severe ...

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

Elon Musk announced plans to make Neuralink's brain-computer interface technology "widely available" following the company's ...

The US Food and Drug Administration (FDA) has granted 'breakthrough device' status to Neuralink’s experimental speech ...

Elon Musk's neurotechnology company Neuralink announced on Thursday (1 May) that it has received the US Food and Drug ...